News >

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

Silas Inman @silasinman
Published: Tuesday, May 29, 2018

Jan van de Winkel, PhD

Jan van de Winkel, PhD
Two separate early-phase clinical trials exploring daratumumab (Darzalex) in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer (NSCLC) were terminated following a planned interim analysis, according to a statement from Genmab, the company codeveloping daratumumab with Janssen.

Another phase II study was exploring durvalumab (Imfinzi) and daratumumab for multiple myeloma; however, this trial was terminated shortly following the mandated partial hold in September 2017. This single-arm trial, however, was stopped due to a lack of efficacy, according to its listing (NCT03000452).
FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA® (pembrolizumab) in Patients with Multiple Myeloma. Accessed August 31, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication